We are live on
!
Find out more
Adage Capital Partners Portfolio holdings
AUM
$64.8B
1-Year Est. Return
42.7%
This Fund
S&P 500
This Quarter
Est. Return
+10.98%
1 Year Est. Return
+42.7%
3 Year Est. Return
+139.29%
5 Year Est. Return
+204.38%
10 Year Est. Return
+829.83%
AUM
$40.7B
AUM Growth
-$4.56M
(-0.01%)
Cap. Flow
-$3.46B
Cap. Flow
% of AUM
-8.5%
Top 10 Holdings %
Top 10 Hldgs %
19.9%
Holding
801
New
88
Increased
169
Reduced
396
Closed
90
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
RTX Corp
RTX
|
+$165M |
| 2 |
Costco
COST
|
+$134M |
| 3 |
Bristol-Myers Squibb
BMY
|
+$126M |
| 4 |
Johnson Controls International
JCI
|
+$121M |
| 5 |
3M
MMM
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CELG
Celgene Corp
CELG
|
+$1.48B |
| 2 |
Apple
AAPL
|
+$136M |
| 3 |
Marathon Petroleum
MPC
|
+$123M |
| 4 |
CenterPoint Energy
CNP
|
+$123M |
| 5 |
Under Armour
UAA
|
+$117M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.42% |
| 2 | Healthcare | 16.85% |
| 3 | Financials | 12.9% |
| 4 | Consumer Discretionary | 10.95% |
| 5 | Industrials | 10.77% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Coherus Oncology
CHRS
$217M
| $4.05M | 0.01% |
225,000
-275,000
| -55% | -$5.07M |
|
|
SILK
627
DELISTED
Silk Road Medical, Inc. Common Stock
SILK
| $4.04M | 0.01% |
100,000
| – | – |
|
628
Unum
UNM
$13.6B
| $3.95M | 0.01% |
135,569
+103,600
| +324% | +$3.01M |
|
629
VF Corp
VFC
$5.63B
| $3.93M | 0.01% |
39,441
-168,100
| -81% | -$15.1M |
|
630
Booz Allen Hamilton
BAH
$8.39B
| $3.91M | 0.01% |
+55,000
| New | +$3.92M |
|
|
ATH
631
DELISTED
Athene Holding Ltd. Class A Common Shares
ATH
| $3.9M | 0.01% |
83,000
-304,724
| -79% | -$13.2M |
|
632
Alerus Financial
ALRS
$831M
| $3.88M | 0.01% |
170,000
-10,000
| -6% | -$220K |
|
633
Coty
COTY
$2.42B
| $3.79M | 0.01% |
336,444
-16,400
| -5% | -$187K |
|
634
Bath & Body Works
BBWI
$4.06B
| $3.78M | 0.01% |
258,027
-83,796
| -25% | -$1.21M |
|
635
Evercore
EVR
$12.4B
| $3.74M | 0.01% |
+50,000
| New | +$3.81M |
|
636
Madrigal Pharmaceuticals
MDGL
$10.8B
| $3.64M | 0.01% |
+40,000
| New | +$3.88M |
|
|
SAGE
637
DELISTED
Sage Therapeutics
SAGE
| $3.61M | 0.01% |
50,000
+30,000
| +150% | +$3.69M |
|
|
AVNS
638
DELISTED
Avanos Medical
AVNS
| $3.37M | 0.01% |
+100,000
| New | +$3.62M |
|
639
Tempest Therapeutics
TPST
$13.7M
| $3.37M | 0.01% |
+2,564
| New | +$3.62M |
|
|
SWAV
640
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $3.29M | 0.01% |
+75,000
| New | +$2.77M |
|
641
Pinterest
PINS
$13.4B
| $3.26M | 0.01% |
175,000
-125,000
| -42% | -$2.7M |
|
|
PR
642
Permian Resources
PR
$17.8B
| $3.23M | 0.01% |
+700,000
| New | +$2.56M |
|
643
Microchip Technology
MCHP
$40.3B
| $3.17M | 0.01% |
60,600
+36,000
| +146% | +$1.74M |
|
644
EverQuote
EVER
$892M
| $3.15M | 0.01% |
91,772
-175,000
| -66% | -$4.88M |
|
|
APLS
645
DELISTED
Apellis Pharmaceuticals
APLS
| $3.06M | 0.01% |
100,000
-400,000
| -80% | -$11.1M |
|
646
Ovintiv
OVV
$17.3B
| $3.05M | 0.01% |
130,024
-1,277,420
| -91% | -$27.4M |
|
647
Alector
ALEC
$168M
| $3.02M | 0.01% |
175,000
| – | – |
|
648
Broadridge
BR
$17.8B
| $2.98M | 0.01% |
24,100
-116,300
| -83% | -$14.2M |
|
|
CBAY
649
DELISTED
Cymabay Therapeutics
CBAY
| $2.94M | 0.01% |
1,500,000
| – | – |
|
650
BILL Holdings
BILL
$4.49B
| $2.85M | 0.01% |
+75,000
| New | +$2.85M |
|
Similar funds
Adage Capital Partners's Q4 2019 Portfolio in Review
As of Q4 2019, Adage Capital Partners held 801 positions worth $40.7B, down 0.01% from $40.7B the previous quarter. Its ten largest holdings account for 20% of the portfolio.
Adage Capital Partners withdrew a net $3.46B in Q4 2019, closing 90 positions and reducing 396 holdings. Its most notable exit was Celgene Corp, an estimated $1.48B position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 16% a quarter earlier, followed by Healthcare and Financials.
Against the trend, Adage Capital Partners opened a new position in Bristol-Myers Squibb worth $142M.
- Adage Capital Partners's largest Q4 2019 buy was Bristol-Myers Squibb: 2,207,539 shares worth $142M.
- Adage Capital Partners added most to RTX Corp in Q4 2019, an estimated $165M increase.
- Adage Capital Partners's biggest Q4 2019 reduction was Apple, cutting an estimated $136M.
- Adage Capital Partners fully exited Celgene Corp in Q4 2019, selling an estimated $1.48B.
- Adage Capital Partners's ten largest holdings make up 20% of its $40.7B portfolio in Q4 2019.
- Adage Capital Partners opened 88 new positions and closed 90 in Q4 2019.
- Adage Capital Partners's portfolio value fell 0.01% quarter-over-quarter to $40.7B.
Based on Adage Capital Partners's 13F filing for Q4 2019, filed 14 Feb 2020.